Replies to post #9435 on Rebus Holdings Inc (RBSH)

[Magnum7419]

As of December 1, 2019, the issuer had 11,383,983 common shares, $0.0001 par value, issued and outstanding.

https://www.otcmarkets.com/filing/html?id=13806748&guid=s5-CUW1ZyVrev3h

[Magnum7419]

"We are a clinical-stage, pre-revenue, pharmaceutical company primarily focused on the development of therapeutics for the treatment of diseases. Through our acquisition of Lewis and Clark Pharmaceuticals, Inc., we currently are focusing on a pipeline of small molecule adenosine receptor modulators."

[Magnum7419]

"Our cash and cash equivalents and restricted cash balances at September 30, 2019 were approximately $50,000, representing 71% of our total assets. Based on our current expected level of operating expenditures, we expect to be able to fund our operations into the first quarter of 2020. "